AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02022215
Drug: Matching Vehicle Solution
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Vehicle Solution, applied once daily for 48 weeks
Trial: NCT02443194
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: after randomization the patient will receive cymbalta/ placebo for 3 months
Trial: NCT00092703
Drug: MK0663, etoricoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00092703
Drug: Comparator: Diclofenac sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02557958
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
Trial: NCT02557958
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
Trial: NCT03770728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous
Trial: NCT01065194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.
Trial: NCT04767178
Drug: Ibuprofen (Sanofi, Istanbul, Turkey)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Each enrolled infant received oral ibuprofen at a dose of 10 mg/kg 60 min before the onset of the eye examination.
Trial: NCT00580580
Drug: PESDA
RxNorm normalized name: Perfluorocarbon-Exposed Sonicated Dextrose Albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injections dosage 0.05-0.20 mL
Trial: NCT01513603
Drug: CLAG-M
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV times 5 days
Trial: NCT01513603
Drug: CLAG-M
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy
Trial: NCT04315792
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Placebo for 3 weeks
Trial: NCT02349607
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placeco
Trial: NCT02349607
Drug: ibuprofen 600 mg
RxNorm normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen 600 mg
Trial: NCT01318278
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy
Trial: NCT02281786
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to RO6926496
Trial: NCT02281786
Drug: RO6926496
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single, ascending dose, intravenous administration
Trial: NCT01327053
Drug: LDE225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
Trial: NCT04278950
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be 2.5mL of saline with brown food coloring.
Trial: NCT01574157
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
Trial: NCT02480166
Drug: 8 weeks SOF/LED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
Trial: NCT02480166
Drug: 12 weeks SOF/LED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
Trial: NCT00422149
Drug: SUBLIVAC® Grasses/Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUBLIVAC® Grasses/Placebo treatment
Trial: NCT00422149
Drug: SUBLIVAC® Grasses treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUBLIVAC® Grasses treatment
Trial: NCT00422149
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment
Trial: NCT01349140
Drug: SKY0402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.
Trial: NCT02130414
Drug: Sandimmun® IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg IV
Trial: NCT02130414
Drug: CyCol® capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 mg CyCol® capsules
Trial: NCT01689714
Drug: Tc 99m EC20
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01049165
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, Oral, 0 mg, Single Dose, 1 day
Trial: NCT00024427
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: High dose 5-FU
Trial: NCT04088448
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg capsule plus Placebo tablet administered once daily after food
Trial: NCT02862691
Drug: Acetaminophen/Oxycodone (Oral analgesic)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once
Trial: NCT00895414
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT03786302
Drug: TAMP bioglass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
Trial: NCT03786302
Drug: Biodentine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
Trial: NCT00521430
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00585221
Drug: Peginterferon-alpha 2b (PegIFNa2b);
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
Trial: NCT00068250
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Five cycles of methotrexate (MTX) at 3.5 gm/m2 administered every two weeks on weeks 1, 3, 5, 7, and 9 via intravenous infusion over four hours once per cycle. Calcium leucovorin 25 mg orally or intravenously every six hours initiated exactly 24 hours following the start of the MTX infusion. Methotrexate levels to be monitored daily, and calcium leucovorin discontinued when the MTX level is less than 10 micromolar.
Trial: NCT00908869
Drug: Vinorelbine, Cyclophosphamide and Interferon alpha 2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Level 1: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 2: Oral Vinorelbine (Navelbine®)20mg x 3/week; oral Cyclophosphamide (Endoxan®) 50mg/day;SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 3: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 5/week.~Level -1 (in case of toxicity at level 1): Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/every 2 days; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week .
Trial: NCT00174863
Drug: SR31747A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03832114
Drug: LNP023
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing doses of LNP023 up to 200 mg.
Trial: NCT00931723
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral treatment twice daily.
Trial: NCT03937648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01683006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous application of placebo during therapeutic hypothermia.~Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering.
Trial: NCT04600505
Drug: Treatment A
RxNorm normalized name: Nix Ultra Lice Treatment And Prevention Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 inhalations of BGF MDI with propellant 1.
Trial: NCT04600505
Drug: Treatment B
RxNorm normalized name: PanOxyl Acne Treatment Bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 2 inhalations of BGF MDI with propellant 2.
Trial: NCT04134247
Drug: PD-1 combined with chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 200 mg，d1; Rituximab 375mg/m2，d0（ the same as the chemotherapy group）~The chemotherapy chooses one of the following:~GDP：Gemcitabine 800-1000mg/m2, d1、8; Cisplatin 25mg/m2, d1-3; Dexamethasone 40mg, d1-4; GemOx：Gemcitabine 800-1000mg/m2, d1、8; Oxaliplatin 130mg/m2，d1; DA-EPOCH：Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5; ICE: Ifosfamide 1g/m２，d1-4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; DICE: Ifosfamide 1 g／m２，dl-d4; Cisplatin 25mg/m２, d1-4; Etoposide 60 mg／m２，d1-4; Dexamethasone 10-20mg，d1-4; High dose MTX（Central recurrence）：MTX 3.5g／ｍ２,ｄ1; Hyper CVAD（B）：MTX 1g／ｍ２, d1; Cytarabine 2-3g／ｍ２, q12h, d2-3
Trial: NCT03352557
Drug: BIIB092
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in treatment arm.
Trial: NCT03352557
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in treatment arm.
Trial: NCT00907803
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules, once daily for 14 days
Trial: NCT02995083
Drug: Normal Saline 10 ml
RxNorm normalized name: normal saline 10 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive an ultrasound guided intra-articular injection of Normal Saline 10 ml
Trial: NCT00888355
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo to losartan tablet q.a.m. , for 12 weeks
Trial: NCT01448824
Drug: LY2484595
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01448824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04338724
Drug: CS1002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose levels will be escalated following a modified 3+3 dose escalation scheme.
Trial: NCT02378194
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 weeks, once daily oral administration
Trial: NCT02378194
Drug: HD-003 (800mg/day)
RxNorm normalized name: Atuss HD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 weeks, once daily oral administration
Trial: NCT02378194
Drug: HD-003 (1600mg/day)
RxNorm normalized name: Atuss HD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 weeks, once daily oral administration
Trial: NCT00586365
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg Naproxen twice a day for two weeks
Trial: NCT03633630
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days
Trial: NCT00539513
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
Trial: NCT00004206
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004206
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004206
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00092872
Drug: MK0557
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02427568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sessions of placebo (with therapy) lasting six to eight hours, scheduled two to four weeks apart.
Trial: NCT00929188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
Trial: NCT02029716
Drug: RTA 408 Lotion 0.5%, 1%, 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02029716
Drug: Lotion vehicle/placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02994953
Drug: M9241 (MTD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received M9241 at M9241 MTD once every 4 weeks until a criterion for treatment discontinuation has been met.
Trial: NCT04627181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1 ml of distilled water injected intramuscularly in the deltoid of the non-fistula arm immediately following HD
Trial: NCT04627181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 100 ml normal saline administered intravenously over 1 hour via the dialysis blood line immediately following HD
Trial: NCT02304926
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: simvastatin (40 mg/day) for 4 weeks
Trial: NCT00964340
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
Trial: NCT00964340
Drug: SRT2104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
Trial: NCT02304926
Drug: Simvastatin + Ezetimibe
RxNorm normalized name: ezetimibe / simvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
Trial: NCT03649152
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule
Trial: NCT02118766
Drug: AN2728 Topical Ointment, 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02118766
Drug: Matching vehicle control
RxNorm normalized name: SUSPENDING VEHICLE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03011970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03199053
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
Trial: NCT00010387
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01057225
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT03746691
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 ml saline IV) will be infused IV over the course of 30 minutes. Volunteers will receive a standard meal, and recordings using high resolution impedance manometry, will be continued for 2 hours.
Trial: NCT02229214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02181361
Drug: hirudin plus aspirin
RxNorm normalized name: hirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: natural hirudin 0.75g, three times a day (Brand name: Maixuekang capsule, Guizhou Xinbang Pharmaceutical Co., China) and aspirin 100mg, once daily
Trial: NCT01571284
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan, 5-FU and leucovorin
Trial: NCT02202512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT02202512
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01608217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (tablet) three times daily for a period of three weeks.
Trial: NCT01608217
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg three times daily for a period of 3 weeks
Trial: NCT01608217
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg three times daily for a period of three weeks
Trial: NCT00529126
Drug: SKY0402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SKY0402
Trial: NCT04213781
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1 µg/kg
Trial: NCT02739529
Drug: Genexol-PM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cremophor EL-free polymeric micelle of paclitaxel
Trial: NCT00278902
Drug: ARRY-334543, EGFR/ErbB2 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
Trial: NCT00241631
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00241631
Drug: Theophylline
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline placebo capcule
Trial: NCT06413420
Drug: Other prescription wake-promoting medications or stimulants
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to at least 1 dose of a prescription wake-promoting medication or stimulant at any time during pregnancy.
Trial: NCT01118520
Drug: perindopril arginine
RxNorm normalized name: Perindopril Arginine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mgs orally daily for the duration of the trial
Trial: NCT01118520
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one daily
Trial: NCT04025593
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750mg/m2 day 1
Trial: NCT04025593
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg/m2 day 1
Trial: NCT01185418
Drug: lactose
RxNorm normalized name: Lactose
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01279629
Drug: Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.
Trial: NCT02345772
Drug: Trastuzumab (H, 8mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.